Skip to main content

Table 1 Baseline (2000) characteristics of the patients in EMECAR

From: Trends towards an improved disease state in rheumatoid arthritis over time: influence of new therapies and changes in management approach: analysis of the EMECAR cohort

Characteristic

All studied patients

Ever used aTNF or LEF

Never used aTNF or LEF

n

789

210 (27%)

579 (73%)

Women

568 (72)

159 (76)*

409 (71)

Age (years)

61 ± 13

57 ± 12***

63 ± 13

Age at rheumatoid arthritis onset (years)

48 ± 15

44 ± 13***

50 ± 15

Rheumatoid factor-positive

592 (75)

167 (79)**

346 (70)

Any comorbidity

606 (77)

154 (73)

380 (77)

Any extra-articular rheumatoid arthritis

355 (45)

122 (58)*

226 (46)

Health Assessment Questionnaire score

1.2 ± 0.9

1.3 ± 0.8

1.2 ± 0.9

Disease activity score from 28-joint count with three parameters

4.1 ± 1.4

4.6 ± 1.4***

3.9 ± 1.3

Larsen score

54 ± 27

57 ± 24

53 ± 27

  1. Data presented as n (%) or as mean ± standard deviation. Characteristics of those patients who used TNF antagonists (aTNF) or leflunomide (LEF) at any time of follow-up were compared with those of patients who did not. ***P < 0.001, **P < 0.01, *P < 0.05.